Biochemical-markers for the diagnosis of bone metastasis: A clinical review

被引:28
作者
Huang, Qian [2 ]
Ouyang, Xuenong [1 ]
机构
[1] Fuzhou Gen Hosp, Dept Oncol, Fujian, Peoples R China
[2] Fujian Univ Tradit Chinese Med, Fujian, Peoples R China
关键词
Malignant tumor; Bone metastasis; Biochemical-markers; ACID-PHOSPHATASE; 5B; CELL LUNG-CANCER; AMINO-TERMINAL PROPEPTIDE; ADVANCED MULTIPLE-MYELOMA; BREAST-CANCER; PROSTATE-CANCER; ALKALINE-PHOSPHATASE; ZOLEDRONIC ACID; RESORPTION MARKERS; SOLID TUMORS;
D O I
10.1016/j.canep.2011.02.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The preferential metastasis of cancer cells to skeleton not only disrupts the process of bone remodeling and influences the therapeutic decision, but also results in severe complications. Although the current diagnosis of bone metastases (BM) relies on bone imaging techniques, they are not sensitive enough for early detection as well as they are invasive and expensive to use. Since factors derived from bone metabolism are potentially useful to diagnose metastatic bone disease in cancer patients, a number of clinical trials have been carried out on this area. Results suggest that higher levels of bone biomarkers are associated with an increased risk of BM. As a result, biochemical-markers are showing prospects in early diagnosis of BM. This review summarizes the available evidence on the clinical use of biochemical-markers in the diagnosis of various cancers with high incidence of BM including breast, prostate and lung. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:94 / 98
页数:5
相关论文
共 65 条
[1]
Role of the metastasis-promoting protein osteopontin in the tumour microenvironment [J].
Anborgh, Pieter H. ;
Mutrie, Jennifer C. ;
Tuck, Alan B. ;
Chambers, Ann F. .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (08) :2037-2044
[2]
Bellahcene A, 1996, J BONE MINER RES, V11, P665
[3]
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[4]
EXPRESSION OF BONE SIALOPROTEIN (BSP) IN DEVELOPING HUMAN TISSUES [J].
BIANCO, P ;
FISHER, LW ;
YOUNG, MF ;
TERMINE, JD ;
ROBEY, PG .
CALCIFIED TISSUE INTERNATIONAL, 1991, 49 (06) :421-426
[5]
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma [J].
Carlinfante, G ;
Vassiliou, D ;
Svensson, O ;
Wendel, M ;
Heinegård, D ;
Andersson, G .
CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (05) :437-444
[6]
Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer [J].
Chang, Yoon Soo ;
Kim, Hyung Jung ;
Chang, Joon ;
Ahn, Chu Min ;
Kim, Sung Kyu ;
Kim, Se Kyu .
LUNG CANCER, 2007, 57 (03) :373-380
[7]
Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis [J].
Chao, Tsu-Yi ;
Wu, Yi-Ying ;
Janckila, Anthony J. .
CLINICA CHIMICA ACTA, 2010, 411 (21-22) :1553-1564
[8]
Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients [J].
Chao, TY ;
Ho, CL ;
Lee, SH ;
Chen, MMJ ;
Janckila, A ;
Yam, LT .
JOURNAL OF BIOMEDICAL SCIENCE, 2004, 11 (04) :511-516
[9]
Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer [J].
Chung, JH ;
Park, MS ;
Kim, YS ;
Chang, J ;
Kim, JH ;
Kim, SK ;
Kim, SK .
YONSEI MEDICAL JOURNAL, 2005, 46 (03) :388-393
[10]
The clinical use of bone resorption markers in patients with malignant bone disease [J].
Coleman, RE .
CANCER, 2002, 94 (10) :2521-2533